Zollinger–Ellison syndrome is associated with complicated ulcer disease of the upper gastrointestinal tract.
While management of Zollinger–Ellison syndrome has dramatically improved with proton pump inhibitor therapy, quality of life in medically treated patients has not been evaluated.
Dr George Smallfield and colleagues prospectively evaluated 52 patients with Zollinger–Ellison syndrome at 6-month intervals over a 3-year period with upper endoscopy, and gastric acid analysis to evaluate the efficacy of current drug therapy and completion of Short-Form 36 v2 forms.
At each 6-month visit, patients’ medication and problem lists were reviewed, comorbidities assessed, and any gastrointestinal symptoms recorded.
|Mental component score did not differ from the general population |
|Digestive Diseases & Sciences|
Co-morbidity was represented as a simple illness count for the main analysis.
The chronic disease score and the Charlson index were used for sensitivity analyses.
The research team found that the unadjusted norm-based estimate of mental component score for 52 patients with Zollinger–Ellison syndrome was 50.
The researchers observed that the unadjusted estimate of the physical component score was 42.
As the number of illnesses or number of medications increased, there was a monotonic decrease in physical component scores.
With multivariable adjustment, the coefficient for number of medications became non-significant.
An increase in each of the co-morbidity indexes was associated with a decrease in physical component scores.
The research team noted that results did not vary by representation of co-morbidity.
Mental component score was not significantly different from the general population.
Dr Smallfield's team concludes, "Patients with medically managed Zollinger–Ellison syndrome have norm-based estimates of the mental component scores as measured by the Short-Form 36 v2 that approximate normal values."
"The physical component scores were decreased with this reduction largely explained by co-morbid illness."